Two questions that decide suitability before anything else

Not every damaged knee is a candidate for a collagen scaffold injection, and knowing why matters as much as knowing what the treatment does. Before anything else, a clinician reviewing a scan for this pathway asks two practical questions: Is the area of cartilage damage geometrically focal — that is, does it have defined borders with reasonably healthy cartilage on all sides? And is the rest of the joint in adequate condition to support repair?

When the answer to either question is 'no', a different pathway is almost certainly more appropriate — and one likely exists. This is not a dead end; it is the decision framework working as it should.

A common misunderstanding is that any cartilage loss, at any severity grade, can be addressed by the same approach. In practice, the pattern of wear matters more than the grade number on a scan report. A large area of diffuse thinning across the whole joint surface raises different questions from a single, contained lesion — even if both carry the same ICRS severity label.

Why defect containment matters as much as defect size

The collagen scaffold used in this pathway works because it acts as a three-dimensional matrix — a physical framework into which the body's own repair cells can migrate. Those cells come from the surrounding native cartilage. As they move into the scaffold they mature into cartilage-producing cells, gradually filling the defect with new tissue.

That mechanism depends entirely on having a viable margin to draw from. Think of the scaffold as a patch: a patch holds only when there is sound material at the edges to anchor to. If the cartilage surrounding a defect is itself worn or absent, there is no healthy tissue at those edges, and the migration process the scaffold relies upon cannot function as intended.

Diffuse joint wear — where thinning is spread across a broad area rather than concentrated in one contained hole — creates exactly this problem. There is no clear border where healthy cartilage ends and the defect begins, and no intact margin to supply repair cells. The scaffold is designed for a focal lesion in an otherwise reasonable joint, not for a surface where degradation has spread widely.

For patients whose scans show this pattern of diffuse wear, the injectable collagen scaffold is not a mismatch in severity — it is a mismatch in mechanism. A different injection pathway, one designed to work across the whole joint surface rather than repair a single site, is typically the more appropriate route.

Defect size: the upper ceiling and the lower threshold

Size is the other dimension clinicians measure on imaging, and it works as a band rather than a single cut-off point.

At the upper end, clinical data suggest an approximate ceiling of around 6 cm² for a single-session scaffold approach. Beyond that threshold, one treatment session may not provide adequate coverage of the affected area, and the case for this pathway weakens. To put 6 cm² in perspective, it is roughly the area of a large postage stamp — not a vast surface, which is why containment (covered in the previous section) and size tend to correlate: truly focal defects rarely exceed this ceiling, while diffuse wear almost always does.

There is also a lower practical threshold, though the evidence does not place it at a precise figure. For very small defects that cause minimal symptoms, a simpler in-clinic injection — without the scaffold step — may be sufficient. The scaffold pathway is positioned for lesions that are too large or complex for a stand-alone injection to address adequately; below that point, adding the scaffold may bring no meaningful benefit over a less involved option.

Size, then, operates as a filter with two ends: too small may not need it; too large may exceed it. The precise lower boundary in centimetres is not established in the available clinical literature, and stating an exact figure would overstate what the evidence supports. What matters practically is that defect dimensions are measured on MRI and assessed at consultation — it is not possible to estimate this from symptoms alone, and a scan is the starting point for any meaningful suitability discussion.

OA grade vs OA pattern: what actually drives the decision

Grading systems can be misleading at the decision stage. Patients often assume that a higher OA grade automatically calls for a more intensive treatment — but the imaging grade alone is not what determines scaffold suitability.

ICRS grading (the scale used to classify cartilage surface damage, where Grade III and IV indicate deep or full-thickness loss) measures severity at a specific site. A patient can have an isolated ICRS Grade III or IV focal defect surrounded by otherwise intact cartilage and still be a reasonable candidate for the scaffold approach, because the geometry is right even though the severity grade is high.

Kellgren-Lawrence grading (the broader scale used to classify overall joint OA on X-ray, from Grade 0 to Grade IV) tells a different part of the story. When Kellgren-Lawrence Grade III or IV changes are diffuse — meaning the wear affects the whole joint surface rather than a single contained lesion — the pattern is generally outside the scope of scaffold-based repair, regardless of how the individual defect grades. End-stage diffuse OA at Kellgren-Lawrence Grade IV, in particular, typically routes toward injection pathways designed to work across the whole joint surface, or toward joint-replacement consideration.

The practical principle is straightforward: the decision axis is focal versus diffuse, not severe versus mild. Diffuse high-grade OA is not without options — it simply points toward a different treatment route, one that does not depend on a contained repair site.

Reactive joints and individual regenerative capacity

Two further variables can redirect the pathway even when defect size and containment look appropriate on imaging.

Joint inflammation

When OA is actively reactive — characterised by rest pain, swelling, or periodic flares — the joint environment may not be well-suited to a scaffold that depends on a stable biological setting for cell migration and tissue formation. In this situation, an injection approach designed to address both pain and inflammation across the joint surface may be clinically preferable. The scaffold pathway requires the right internal conditions; a highly reactive joint may not provide them, making a non-scaffold injection route — or a combined approach targeting both symptoms and inflammation — a more appropriate starting point.

Regenerative capacity

The scaffold works by recruiting the body's own repair cells into the collagen matrix, which means the body's capacity to generate new tissue is a relevant consideration. This is assessed individually at consultation, taking into account the overall clinical picture rather than any single marker such as age or OA grade in isolation. By contrast, injection pathways focused primarily on symptom relief and joint support do not depend on the patient producing new cartilage in the same way — which is why they remain an option across a broader range of patients and circumstances.

Neither factor is an automatic disqualifier. Both are part of the assessment conversation, weighed alongside imaging findings and symptoms, before a clinician recommends a direction.

What the alternatives look like when the scaffold approach is not suitable

Patients who fall outside scaffold candidacy — whether because of diffuse wear, a reactive joint, or limited regenerative capacity — have several injection pathways worth discussing at consultation.

A hydrogel such as Arthrosamid® works on a different principle from a scaffold: rather than supporting a focal repair site, it integrates with existing joint tissue to cushion and support the surface across a wider area. For diffuse OA with an inflammatory component, a combined approach pairing a joint-support hydrogel with other intra-articular treatments is one route that evidence supports.

Hyaluronic acid viscosupplementation — while not regenerative — addresses joint lubrication and may offer symptomatic benefit for patients managing moderate, widespread OA. Platelet-rich plasma (PRP) is a biologic option that some studies suggest may support the joint environment, though preparation protocols and evidence quality vary between centres.

For end-stage joint disease where injection pathways are insufficient, surgical routes — including osteochondral grafting or joint replacement — exist as separate clinical pathways best explored with an orthopaedic specialist.

Not being a candidate for one approach does not mean running out of options. The suitability assessment at amsk.co.uk is a practical first step toward understanding which pathway fits your specific presentation.